Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2006

View Archived Issues

Axcan updates developments of its second quarter

Activity of SP-304 assessed in experimental colitis

GenVec files quarterly report

Phase III study begins for Rylomine for severe postoperative orthopedic pain

Newer antiepileptic drugs show potential in cyclic vomiting syndrome

Paricalcitol improves bone strength in renal bone disease model

Antihypertensive effect of CI-1027 alone and with quinapril assessed in vivo

Quetiapine shows potential as monotherapy in bipolar depression

Three new mechanism-of-action studies begin for VNS Therapy

New phase III study evaluates HuMax-CD20 for refractory B-cell CLL

Peg-Intron studied in liver transplant recipients with recurrent hepatitis C

FDA gives 510(k) clearance for SynVitro Cumulase

Topigen begins phase II program for TPI-1020 in respiratory disorders

Pharmacopeia and Cephalon form drug discovery and development alliance

Plans for phase II study of interferon alpha for oral warts in HIV patients

New personalized treatment study for breast cancer

Vertex begins new phase II studies of VX-950 in treatment-naive HCV patients

Xoma and Schering-Plough collaborate on antibody discovery and development

Cloretazine begins pivotal study in elderly poor risk AML patients

Apilimod mesylate studied for rheumatoid arthritis and CVID in two new studies

Novel therapeutic agents for thrombosis and related disorders reported in recent patents

Agents for metabolic disorders disclosed

Novel agents for gastrointestinal disorders disclosed in recent patent literature

FGF analogue, fibratide, beneficial in experimental inflammation

Recombinant soluble interleukin-1 receptor type II Fc fusion protein effective in CD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...